Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Defects, Congenital | 6 | 2024 | 1830 | 0.650 |
Why?
|
| Hypothermia, Induced | 1 | 2019 | 170 | 0.570 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2017 | 354 | 0.490 |
Why?
|
| Weight Gain | 1 | 2017 | 400 | 0.470 |
Why?
|
| Monitoring, Physiologic | 2 | 2016 | 377 | 0.470 |
Why?
|
| Heart Arrest | 1 | 2019 | 357 | 0.460 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2016 | 143 | 0.440 |
Why?
|
| Coronary Care Units | 1 | 2013 | 35 | 0.430 |
Why?
|
| Critical Care | 3 | 2016 | 657 | 0.400 |
Why?
|
| Down Syndrome | 1 | 2013 | 197 | 0.360 |
Why?
|
| Pain, Postoperative | 1 | 2013 | 259 | 0.350 |
Why?
|
| Hemodynamics | 1 | 2013 | 851 | 0.320 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 408 | 0.320 |
Why?
|
| Heart Diseases | 1 | 2013 | 496 | 0.310 |
Why?
|
| Obesity | 1 | 2017 | 2249 | 0.260 |
Why?
|
| Postoperative Complications | 1 | 2017 | 3055 | 0.250 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2016 | 145 | 0.220 |
Why?
|
| Oximetry | 2 | 2016 | 171 | 0.210 |
Why?
|
| Heart Failure | 1 | 2016 | 2298 | 0.200 |
Why?
|
| Teaching Rounds | 1 | 2022 | 28 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 438 | 0.170 |
Why?
|
| Heart Ventricles | 1 | 2024 | 777 | 0.160 |
Why?
|
| Asphyxia | 1 | 2019 | 14 | 0.160 |
Why?
|
| Health Information Systems | 1 | 2019 | 31 | 0.150 |
Why?
|
| Linear Models | 2 | 2017 | 687 | 0.150 |
Why?
|
| Risk Adjustment | 1 | 2017 | 58 | 0.140 |
Why?
|
| Palivizumab | 1 | 2017 | 47 | 0.140 |
Why?
|
| Chlorothiazide | 1 | 2016 | 12 | 0.130 |
Why?
|
| Nephrons | 1 | 2016 | 20 | 0.130 |
Why?
|
| Diuresis | 1 | 2016 | 58 | 0.130 |
Why?
|
| Child Development | 1 | 2019 | 266 | 0.130 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 10 | 0.130 |
Why?
|
| Alprostadil | 1 | 2015 | 27 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 542 | 0.120 |
Why?
|
| Cardiac Output | 1 | 2016 | 171 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 229 | 0.120 |
Why?
|
| Humans | 12 | 2024 | 125331 | 0.110 |
Why?
|
| Heart | 1 | 2019 | 731 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 202 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 715 | 0.110 |
Why?
|
| Infant | 5 | 2024 | 12581 | 0.110 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2013 | 15 | 0.110 |
Why?
|
| Consensus | 1 | 2017 | 644 | 0.110 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2017 | 345 | 0.110 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8259 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 514 | 0.100 |
Why?
|
| Critical Illness | 1 | 2016 | 601 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2017 | 1562 | 0.090 |
Why?
|
| Infant, Premature | 1 | 2016 | 830 | 0.090 |
Why?
|
| Length of Stay | 1 | 2015 | 1311 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3439 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16344 | 0.080 |
Why?
|
| Male | 7 | 2024 | 61573 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2175 | 0.070 |
Why?
|
| Female | 7 | 2024 | 66836 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2024 | 12290 | 0.070 |
Why?
|
| Pregnancy | 1 | 2017 | 7219 | 0.060 |
Why?
|
| Brain | 1 | 2016 | 3009 | 0.060 |
Why?
|
| Prognosis | 1 | 2013 | 4677 | 0.060 |
Why?
|
| Young Adult | 1 | 2017 | 9066 | 0.050 |
Why?
|
| Ductus Arteriosus | 1 | 2024 | 62 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1691 | 0.050 |
Why?
|
| Professional-Family Relations | 1 | 2022 | 93 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2024 | 14123 | 0.040 |
Why?
|
| Child | 2 | 2022 | 24575 | 0.040 |
Why?
|
| Family | 1 | 2022 | 567 | 0.040 |
Why?
|
| Texas | 2 | 2019 | 3582 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 492 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5166 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2022 | 545 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2024 | 960 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2022 | 765 | 0.040 |
Why?
|
| Adult | 1 | 2017 | 29607 | 0.030 |
Why?
|
| Furosemide | 1 | 2016 | 38 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 248 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2017 | 147 | 0.030 |
Why?
|
| Birthing Centers | 1 | 2015 | 10 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 478 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 308 | 0.030 |
Why?
|
| Diuretics | 1 | 2016 | 171 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 248 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 1174 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1428 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2017 | 765 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3134 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 1122 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 10287 | 0.010 |
Why?
|